CTP Imaging of Lung Cancer

CTP (Computed Tomography Perfusion) Imaging of Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01823094

Acronym

CTPLC

Enrollment

Registered

2013-04-04

Start date

2013-03-31

Completion date

2015-06-30

Last updated

2016-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Keywords

lung cancer, computed tomography, blood flow

Brief summary

Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body. Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.

Detailed description

This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy

Exclusion criteria

renal failure pregnancy known contrast allergy \-

Design outcomes

Primary

Measure	Time frame	Description
Yield of conducting CTP studies	2 years	Yield is determined as the percentage of assessable CTP studies, relative to all performed studies

Secondary

Measure	Time frame	Description
Variability of CTP measurements	2 years	Variability will be determined from two consecutively acquired CTP examinations, and repeated analyses of the same studies
Magnitude of treatment induced changes in tumor blood flow	2 years	The magnitude of treatment induced changes in blood flow will be determined from comparisons of bloodflow before and after treatment

Countries

United States

Outcome results